Published in:
01-07-2011 | Original Paper
Spinal cord tumors in children under the age of 3 years: a retrospective Canadian review
Authors:
Shayna Zelcer, Daniel Keene, Ute Bartels, Anne-Sophie Carret, Bruce Crooks, David D. Eisenstat, Chris Fryer, Lucie Lafay-Cousin, Donna L. Johnston, Valerie Larouche, Albert Moghrabi, Beverly Wilson, Mariana Silva, Josee Brossard, Eric Bouffet
Published in:
Child's Nervous System
|
Issue 7/2011
Login to get access
Abstract
Background
Tumors of the spinal cord are exceedingly rare in infancy and only a paucity of literature exists describing the spectrum of this disease and its management. The objectives of our study were to describe the demographic characteristics of spinal cord tumors (SCT) in children less than 3 years of age at diagnosis and to review their treatment and outcome.
Methods
A national retrospective chart review was conducted on patients under the age of 3 years diagnosed with a primary tumor of the central nervous system (CNS) between 1990 and 2005 across Canada. Inclusion criteria were: age ≤3 years, histologic confirmation of the diagnosis, and residency in Canada. A centralized database was created and information regarding SCT was extracted.
Results
Twenty-five of five hundred seventy-nine patients (4.3%) in the data bank had a SCT. The majority of tumors were low-grade astrocytomas (14/25). Leptomeningeal dissemination based on neuroradiologic imaging and/or cerebrospinal fluid cytology was present in five (20%) patients. The majority of patients underwent an incomplete surgical resection (52%). Most patients (64%) did not receive postoperative radiotherapy or chemotherapy. Seventy-two percent (18/25) developed recurrent/progression of disease. Overall 2- and 5-year survival for low- and high-grade malignancies was 93 ± 6.4% and 37.5 ± 17.1% respectively. Significant predictors of survival included mean duration of symptoms prior to initial diagnosis and recurrence/progression of disease.
Conclusions
Relapse/progression of disease in infant SCT is frequent. Prolonged survival of low-grade tumors is possible with further therapy; however, the prognosis of high-grade malignancies remains poor.